ライフサイエンスコーパス: ferric citrate

1 or CV1-FHC, 2.9 +/- 0.3 x 10(-3) for CV1-FHC-ferric citrate).

2 moglobin levels were statistically higher on ferric citrate.

3 C (ferric citrate-binding protein C)], binds ferric citrate.

4 ast Saccharomyces cerevisiae were grown with ferric citrate.

5 al transitions in response to the binding of ferric citrate.

6 ed in MCF-7 cells cultured with supplemental ferric citrate.

7 ited equivalent rates of uptake of 55Fe from ferric citrate.

8 f serious adverse events were similar in the ferric citrate (12.0%) and placebo groups (11.2%).

9 travenous elemental iron (median=12.95 mg/wk ferric citrate; 26.88 mg/wk active control; P<0.001) and

10 tin-equivalent units per week: 5306 units/wk ferric citrate; 6951 units/wk active control; P=0.04).

11 Subjects on ferric citrate achieved higher mean iron parameters (fer

12 Significantly more patients randomized to ferric citrate achieved the primary end point (61 [52.1%

13 ontrol period phosphorus was similar between ferric citrate and active control, with comparable safet

14 e clusters that likely serve in transport of ferric citrate and ferrioxamine.

15 mpared the mean change in phosphorus between ferric citrate and placebo during the placebo control pe

16 (18.8%) and 15 (12.9%) patients treated with ferric citrate and placebo, respectively.

17 reus ATCC 14579 takes up (55)Fe radiolabeled ferric citrate and that a protein, BC_3466 [renamed FctC

18 suppressor mutant, respiration of fumarate, ferric citrate, and DMSO was restored but that of nitrat

19 t labile, and could utilize ferric chloride, ferric citrate, and human holotransferrin as substrates.

20 it binds and transports iron in the form of ferric citrate, and second, it initiates a signaling cas

21 We studied ferric citrate as a phosphorus binder and iron source.

22 with hemoglobin, transferrin, ferritin, and ferric citrate as iron sources.

23 e wild-type parent strain when supplied with ferric citrate as the iron source.

24 FecA from Escherichia coli with and without ferric citrate at 2.5 and 2.0 angstrom resolution.

25 es transcriptional activation in response to ferric citrate binding at the cell surface.

26 ferric citrate import system is regulated by ferric citrate binding to the outer membrane transporter

27 e and that a protein, BC_3466 [renamed FctC (ferric citrate-binding protein C)], binds ferric citrate

28 n characterized; little is known about other ferric citrate-binding proteins.

29 -dichlorophenolindophenol, several quinones, ferric citrate, bovine cytochrome c, and O(2) accepted e

30 fashion and c-myc expression was enhanced by ferric citrate compared to sodium citrate control.

31 sting that iron moves through the xylem as a ferric-citrate complex.

32 ctrometry (nano ESI-MS) analysis of FctC and ferric citrate complexes or citrate alone show that FctC

33 rium Bacillus cereus that binds multinuclear ferric citrate complexes.

34 Ferric citrate controlled phosphorus compared with place

35 that were most responsive to the presence of ferric citrate did not follow a trend similar to that of

36 Ferric citrate (FC) is a phosphate binder with shown eff

37 uptake systems for elemental iron (efeUOB), ferric citrate (fecCDEF), and petrobactin (fpbNOPQ) are

38 t be reversed by the addition of iron salts, ferric citrate, ferric nitrate, or ferric transferrin.

39 and TBI uptake, we injected (59) Fe-labeled ferric citrate (for NTBI) or (59) Fe-transferrin into pl

40 r the control group versus 84.7 mg/d for the ferric citrate group (P < 0.005).

41 ints reached statistical significance in the ferric citrate group, including the mean relative change

42 Transcription of the ferric citrate import system is regulated by ferric citr

43 transcriptional activation is not coupled to ferric citrate import, an allosteric mechanism underlies

44 Thus, ferric citrate is an efficacious and safe phosphate bind

45 , and O(2), as well as the ability to reduce ferric citrate, manganese(IV), nitrate, and nitrite.

46 ation constant (K(d)) of FctC at pH 7.4 with ferric citrate (molar ratio 1:50) is 2.6 nM.

47 a to compare the safety and efficacy of oral ferric citrate (n=117) and placebo (n=115).

48 ide (TMAO), thiosulfate, dimethyl sulfoxide, ferric citrate, nitrate, and O(2), as well as the abilit

49 441 subjects on dialysis were randomized to ferric citrate or active control in a 52-week active con

50 e active control period were rerandomized to ferric citrate or placebo.

51 Only the Escherichia coli ferric citrate outer-membrane transport protein FecA has

52 Subjects on ferric citrate received less intravenous elemental iron

53 r, inhibited Zip14-mediated iron uptake from ferric citrate, suggesting that iron is taken up by HEK

54 all, in patients with NDD-CKD, we found oral ferric citrate to be a safe and efficacious treatment fo

55 Many bacteria and plants use ferric citrate to fulfill their nutritional requirement

56 lis strains were found to be able to utilize ferric citrate, transferrin, lactoferrin, and heme as so

57 transporter initiate two independent events: ferric citrate transport into the periplasm and transcri

58 sized and transported enterobactin and had a ferric citrate transport system but lacked the ability t

59 t transporters, such as the Escherichia coli ferric citrate transporter FecA, interact with the inner

60 cribe three structures of the outer membrane ferric citrate transporter FecA: unliganded and complexe

61 plasmic ferric transport protein, a putative ferric citrate transporter, and ferritin, respectively.

62 In the ferric citrate transporter, FecA, SDSL indicates that th

63 , the vitamin B12 transporter, and FecA, the ferric citrate transporter.

64 treated group (P = 0.058), 77.0 mg/d for the ferric citrate-treated group (P = 0.057), and 62.5 mg/d

65 Binding of ferric citrate triggers a conformational change of the e

66 d to encode homologs of the Escherichia coli ferric citrate uptake regulators FecI and FecR.

67 Reduction of ferric citrate was accompanied by oxidation of the cytoc

68 upplemented with hemoglobin, whole blood, or ferric citrate was not affected, suggesting additional s

69 placebo control period, in which subjects on ferric citrate who completed the active control period w